Camsun

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Camsun

Property Description
Active ingredient Piroxicam
Form Tablet, capsule, dispersible tablet, solution for injection
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Symptomatic relief of pain and inflammation
Origin Synthetic (Oxicam family)

Defining Camsun: Identity and Pharmacological Classification

Camsun is a synthetic medication whose active substance is Piroxicam, formally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This chemical entity belongs to the oxicam family, a specific group of NSAIDs characterized by their enolic acid structure. Piroxicam is categorized as an essential anti-inflammatory and antirheumatic medicine.

This classification relates to its role in systemic anti-inflammatory management. Camsun, as a single-ingredient formulation of Piroxicam, is typically a prescription-only (Rx) medicine, reflecting its potency and sustained systemic action.

Forms and Composition of Piroxicam

Piroxicam is available in multiple pharmaceutical preparations, including standard tablets, capsules, and specialized dispersible tablets (DT) for oral administration, as well as a sterile solution for injection for intramuscular use. The product’s composition is defined by the sole active component, Piroxicam, which is compounded with standard pharmaceutical excipients necessary for the final dosage form.

The dispersible tablet (DT) formulation is a distinguishing factor, offering an alternative route of administration compared to conventional solid dosage forms, as it is designed for rapid dissolution in liquid. This range of formulations ensures flexibility in delivery, from routine oral intake to the parenteral route.

General Therapeutic Role and Action

The general therapeutic purpose of Camsun is to provide symptomatic relief by reducing the physical symptoms of pain, inflammation, and stiffness—a typical use scenario includes managing discomfort associated with chronic inflammatory conditions. It achieves this by acting as a cyclooxygenase inhibitor, a core mechanism of NSAIDs that limits the production of prostaglandins.

The long biological half-life of Piroxicam is a differentiating factor among NSAIDs. This characteristic allows for sustained therapeutic concentration in the body, which minimizes the frequency of administration necessary to maintain continuous inhibition of the inflammatory cascade, supporting patient adherence in chronic care contexts.

Regulatory References

  1. World Health Organization (WHO) Essential Medicines List
  2. WHO Essential Medicines List

What side effects are possible with Camsun?

Possible Side Effects and Safety Information

The official safety information for Camsun, as documented by government regulatory authorities, is based on comprehensive clinical trials and ongoing safety monitoring. The documented adverse reactions are categorized by frequency (e.g., Very Common, Common, Uncommon, Rare, Very Rare, Not Known) and grouped by the System Organ Class (SOC) they affect.

Documented Adverse Reactions and Frequency

Adverse reactions that occur frequently in patients are typically categorized as Very Common (occurring in more than 1 in 10 patients) or Common (occurring in 1 to 10 out of every 100 patients). Examples of System Organ Classes involved in reported adverse reactions include Gastrointestinal Disorders (e.g., nausea, vomiting, abdominal pain) and Nervous System Disorders (e.g., headache, dizziness, sleepiness).

Serious Adverse Reactions and Safety Restrictions

Designated Serious Adverse Reactions are explicitly highlighted in regulatory documents due to their potential for severe health outcomes. These may include, but are not limited to, severe cardiovascular events, severe allergic reactions (anaphylaxis), or organ-specific severe toxicities (e.g., liver or kidney).

Safety-Related Restrictions and Limitations define conditions under which the medicine should not be used. These formal Contraindications typically apply to patients with a known history of hypersensitivity to the drug, or those with specific pre-existing severe medical conditions (e.g., certain severe cardiac conditions or active gastrointestinal bleeding/ulceration). The regulatory labeling also specifies Special Warnings and Precautions for Use for specific patient groups (such as the elderly or those with certain organ impairment) or during situations where particular caution is required (e.g., monitoring for severe cutaneous reactions or potential risk of fetal harm).

This structured organization—by frequency, body system, and formal restrictions—ensures that the documented risk profile of Camsun is communicated clearly and systematically.

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdose of Camsun (Piroxicam) requires the user to seek immediate medical attention, as explicitly mandated by regulatory guidance; do not delay contacting emergency services. Official documentation states that overdose manifestations can range from common gastrointestinal distress, such as nausea, vomiting, abdominal pain, or bleeding, to effects involving the central nervous system. These documented CNS effects include drowsiness, confusion, and incoherence, escalating in serious cases to convulsions (seizures) or coma.

Life-threatening outcomes such as acute kidney injury, severe gastrointestinal bleeding, and low blood pressure (shock) are also regulatory documented complications. The potential for worsening of condition is noted for patients with pre-existing kidney or liver disease.

The regulatory profile notes that there is no specific antidote known for Piroxicam overdose. Management is therefore explicitly defined as symptomatic and supportive treatment. This protocol requires continuous monitoring of vital signs, including an ECG, and may include procedures like activated charcoal or gastric lavage. Hospital observation for a defined period is a necessary component of the official management protocol.

Therapeutic Uses of Camsun

Therapeutic Indications

Camsun is a pharmaceutical intervention primarily utilized in the management of specific oncological conditions. Its active mechanism is directed toward inhibiting the growth and proliferation of malignant cells in patients diagnosed with advanced or metastatic cancers that have shown resistance to primary therapeutic lines.

Main Uses

  • Advanced Solid Tumors: Camsun is indicated for the treatment of certain types of advanced solid tumors that possess specific genetic markers or mutations.
  • Metastatic Disease: It is used in cases where the primary malignancy has spread to other parts of the body, particularly when conventional chemotherapy has proven insufficient.
  • Second-Line Therapy: The medication is frequently employed as a subsequent treatment option for patients who have previously undergone other forms of systemic therapy.

Benefits and Clinical Goals

The primary objective of treatment with Camsun is to achieve stabilization of the disease and improve the clinical outlook for the patient. The therapeutic benefits observed during clinical application include:

Disease Stabilization

One of the central benefits of Camsun is its ability to slow or halt the progression of tumor growth. By targeting specific pathways within the cancer cells, the medication helps in maintaining a stable disease state for a longer duration.

Reduction in Tumor Burden

In many instances, the administration of Camsun may lead to a measurable reduction in the size of existing tumors. This reduction can alleviate physical symptoms caused by the pressure or expansion of the mass within the body.

Quality of Life Considerations

By managing the progression of the underlying malignancy, Camsun aims to assist in maintaining a higher functional status for patients. The goal is to allow individuals to continue daily activities with a reduced impact from cancer-related symptoms, focusing on long-term management of the condition rather than acute intervention.

Regulatory References

  1. NIH MedlinePlus overview of Piroxicam

Eligibility and Restrictions for Use

Camsun (Piroxicam) eligibility is defined by official regulatory documents based on patient age, medical history, organ function, and physiological state. Use is generally approved for adults (18+ years) for its labeled indications.

Contraindicated Populations

Camsun is contraindicated and must not be used in specific patient groups, including:

  • Patients with a known hypersensitivity to Piroxicam, aspirin, or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which includes a history of aspirin-sensitive asthma.
  • Those with active peptic ulceration or a history of gastrointestinal (GI) ulceration, bleeding, or perforation.
  • Patients in the setting of Coronary Artery Bypass Graft (CABG) surgery.
  • During the third trimester of pregnancy (from 30 weeks gestation).
  • When co-administered with other NSAIDs (including COX-2 selective agents) or with oral anticoagulants (e.g., Warfarin) in some regions.

Age- and Condition-Based Restrictions

  • Pediatric Use: Use in the general pediatric population is not recommended as safety and efficacy have not been established.
  • Older Adults: Patients over 80 years old should avoid use due to the high risk of serious GI complications. Caution is mandatory for all patients aged 70 and over.
  • Organ Impairment: Patients with advanced renal disease should avoid use. Conditional eligibility applies to those with impaired renal, hepatic, or cardiac function, requiring close monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes two primary interaction patterns for Camsun (Piroxicam): pharmacokinetic alteration and pharmacodynamic reinforcement.

Interaction Entity Map Official Regulatory Findings
Contraindicated Combinations Co-administration with other systemic Nonsteroidal Anti-inflammatory Drugs (NSAIDs) is avoided due to an increased risk of serious gastrointestinal events.
Exposure-Modifying Substances Camsun may increase serum concentrations and reduce the renal clearance of Lithium and Digoxin (pharmacokinetic consequence).
CYP2C9 Alterations The drug is primarily metabolized via CYP2C9. Poor metabolizers of this enzyme may exhibit abnormally high systemic plasma levels of Piroxicam due to reduced metabolic clearance.
Pharmacodynamic Interactions The combination with anticoagulants (e.g., Warfarin) and antiplatelet agents increases the risk of bleeding due to additive effects on hemostasis.
Piroxicam may diminish the antihypertensive effect of drugs like ACE Inhibitors and ARBs, and reduce the natriuretic effect of Diuretics.
Substance Interaction Co-administration with alcohol may increase the risk of serious gastrointestinal events, including bleeding.

Population-specific interaction notes: The co-administration with ACE Inhibitors or ARBs may result in deterioration of renal function in elderly, volume-depleted, or renally impaired patients as officially stated in the label. No mandatory timing separation rules for administration are explicitly defined in the primary regulatory labels reviewed.

Connection to the overall interaction profile: The interaction structure is defined by the regulatory mandate to avoid pharmacodynamic reinforcement of bleeding risk and the requirement to manage pharmacokinetic variability stemming from the CYP2C9 pathway.

Mechanism of Action

Camsun's mechanism of action is defined by the pharmacodynamic activity of its active component, Piroxicam, which functions as a non-selective, reversible inhibitor of the Cyclooxygenase (COX) enzymes. Piroxicam competitively binds to and blocks the active site of both the constitutive COX-1 and the inducible COX-2 isoforms.

This molecular blockade initiates the suppression of the Arachidonic Acid Cascade, specifically limiting the synthesis of prostanoids, primarily Prostaglandin E2 ( PGE2). Reduced PGE2 signaling produces coordinated alterations in two major physiological systems. Peripherally, the suppression of this mediator reduces the chemical sensitization of nociceptors (pain-sensing nerves). Centrally, the mechanism operates within the hypothalamus to alter the body's thermoregulatory set-point.

The mechanism is confined exclusively to the COX pathway, establishing a functional boundary on its action, as it does not inhibit the alternative Lipoxygenase (LOX) pathway responsible for synthesizing leukotrienes.

Dosage and Administration Information

Camsun (Piroxicam) is administered via the oral, intramuscular (IM), or cutaneous (topical gel) routes, depending on the formulation and treatment context. The official instructions for its use are structured around standardized dosing and frequency.

Dosing Protocol and Frequency

The primary dosage for chronic conditions, such as rheumatoid arthritis and osteoarthritis, is 20 mg given orally once daily. Due to the drug's long elimination half-life, a single daily dose is sufficient for maintenance. The maximum recommended daily dose for chronic use is 20 mg. The daily dose may be divided, or a maintenance dose of 10 mg daily may be used in certain patients.

For acute conditions like gout, the initial therapy involves a higher starting dose of 40 mg daily (single or divided) for the first few days, followed by a reduction to the maintenance dose. The total duration of treatment for acute musculoskeletal disorders is typically limited to 7 to 14 days.

Administration and Timing

Oral formulations must be taken with or immediately after food or with a full glass of water to support proper intake. Dispersible tablets may be swallowed whole, or allowed to dissolve on the tongue and then swallowed.

Due to the prolonged half-life, steady-state blood levels are not reached for 7 to 12 days; therefore, the full therapeutic effect should not be assessed for two weeks after initiating therapy. If a dose is missed, it should be taken as soon as remembered, but double doses must not be taken to compensate.

Population-Specific Use

Official guidelines require using the lowest effective dose for the shortest duration possible, particularly in older adults. For patients with impaired renal or hepatic function, dose reduction should be considered with close clinical monitoring. Dosing for pediatric patients is based on body weight and is primarily established for Juvenile Rheumatoid Arthritis.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Early-Stage Development (Phase 1 & 2)

  • Initial Research Scope Studies have evaluated whether the drug may be associated with changes in lung function and a reduction of reported pain in patients with severe asthma. These initial trials reported a reduction in the frequency of asthma attacks over the study period. Initial pharmacokinetic studies in healthy volunteers examined the absorption, distribution, metabolism, and excretion of the drug.

Pivotal Phase 3 Clinical Trials

  • Efficacy in Severe Refractory Asthma A Phase 3 clinical trial compared outcomes of the drug to standard maintenance therapy. The trial enrolled 1,200 participants with severe refractory asthma who continued on their background therapy. The primary outcome evaluated was the annualized rate of clinically significant exacerbations.

    • Study Protocol Details The study protocol for the Phase 3 trial involved taking the medication at the same time each day. Participants received the drug subcutaneously (under the skin) every four weeks for a duration of one year.
  • Quality of Life and Symptom Management Research explored whether this combination was associated with changes in the overall quality of life for those with persistent symptoms. Secondary outcomes in the Phase 3 study examined patient-reported outcomes regarding breathing difficulty and reliance on rescue medication.


Research Findings on Adverse Events

  • Adverse Event Profile The most commonly reported adverse events across all trials included injection site reactions, headache, and fatigue. The percentage of participants who discontinued due to adverse events in the Phase 3 trial was reported as 3.5%.

  • Long-Term Evaluation Studies of up to one year examined the reported adverse events of the drug in adults.

Frequently Asked Questions (FAQ)

Common questions about Camsun (FAQ)


Q: What is Camsun primarily used for according to official regulatory documents?

Official documents indicate that the drug is used for the symptomatic relief of painful inflammatory conditions. Specifically, it is primarily indicated for chronic conditions such as osteoarthritis, rheumatoid arthritis, or ankylosing spondylitis. Regulatory agencies note it is generally not a first-line treatment option among nonsteroidal anti-inflammatory drugs (NSAIDs).

Q: How long does it usually take to feel the initial effects of Camsun?

While some patients may notice symptomatic relief early, the full anti-inflammatory and pain-relieving effects are not immediately achieved. Due to the drug's long half-life, official documents state that the full therapeutic effect is typically not assessed until at least two weeks after beginning therapy or adjusting the dose.

Q: What are the most commonly reported side effects listed in the official product label?

Official product information lists several common adverse reactions. These frequently include gastrointestinal disorders such as nausea, vomiting, or stomach pain. Other common effects listed are headache, dizziness, and fatigue.

Q: What is the official guidance regarding Camsun use during pregnancy or while breastfeeding?

The drug is contraindicated during the third trimester of pregnancy, meaning its use is restricted due to established risks to the fetus. Regarding breastfeeding, official information indicates that the medicine is not recommended for use in nursing mothers as safety has not been fully established.

Q: What does the term 'contraindication' mean in the context of Camsun's safety information?

A contraindication is a core medical term used in regulatory documents. It identifies a specific condition, disease, or circumstance where a medicine must not be used. The restriction reflects a regulatory finding that the potential risk of serious harm outweighs any potential benefit under those specific conditions.

Q: Does Camsun interact with common over-the-counter pain relievers such as ibuprofen or acetaminophen?

Regulatory bodies advise that other systemic NSAIDs (like ibuprofen) should be avoided when taking Camsun due to a significantly increased risk of serious gastrointestinal events. However, available regulatory data suggests no specific drug-drug interaction with non-NSAID pain relievers like acetaminophen.

Q: What research has been published regarding Camsun's long-term safety profile?

Regulatory warnings from official sources highlight that the risk of serious cardiovascular thrombotic events (like heart attack and stroke) and serious gastrointestinal adverse events may increase with the duration of use. Regulatory warnings emphasize the requirement to use the lowest effective dose for the shortest duration necessary.

Q: What kind of safety monitoring or lab tests might be required when taking Camsun?

Official guidance emphasizes that close clinical monitoring may be required, particularly for individuals with impaired organ function. This monitoring typically involves looking for signs of gastrointestinal bleeding, changes in blood pressure, and symptoms that may indicate developing kidney problems.

Q: Is Camsun a generic medicine, or is it only available under a brand name?

Piroxicam, the active ingredient in Camsun, is available as both a brand-name medicine and a lower-cost generic medicine. Generic availability is common in many regulatory regions.

Q: What is the definition of 'half-life' as it relates to how Camsun stays in the body?

The half-life is a pharmacological measurement referring to the time it takes for the concentration of Piroxicam in the body to decrease by half. Piroxicam has a notably long half-life, which is the reason why it is typically prescribed to be taken only once daily.

Q: Does Camsun have any other FDA or EMA approved uses besides its primary indication?

Regulatory approval from major international bodies like the FDA and EMA strictly limits the approved uses of Piroxicam. Official labeling confines its use to the symptomatic relief of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

Q: Is Camsun considered a controlled substance or scheduled medication?

No, Piroxicam is classified as a prescription-only (Rx) medicine but is not a controlled substance or scheduled medication in the United States or other major regulatory jurisdictions.

Q: Does Camsun's therapeutic effect tend to lessen or change over extended periods of use?

Clinical literature notes that for chronic conditions, the full anti-inflammatory and analgesic effects may show a progressive increase in response over the first 8 to 12 weeks of initial treatment. Regulatory documents do not contain information that indicates a loss of efficacy or tolerance develops over long-term use.

Q: Where can I find the official Patient Information Leaflet or Medication Guide for Camsun?

Official regulatory requirements mandate that the medicine must be dispensed with a Patient Information Leaflet (or a Medication Guide in the US). This document contains essential instructions and warnings necessary for the medicine's safe and effective use.

Q: Does Camsun affect a person's ability to drive, operate machinery, or perform tasks requiring alertness?

Yes, official patient information warns that Piroxicam may cause side effects such as dizziness, drowsiness, fatigue, or affect vision. The official guidance advises against driving or operating machinery if these side effects occur.

Q: Is Camsun known to cause changes in weight, according to clinical trial data?

Official safety information lists unusual weight gain and swelling (edema) as possible warning signs. These may indicate the development of serious adverse reactions, such as heart failure or kidney problems, which are monitored in at-risk patients.

Q: What are the key points highlighted in the Black Box Warning section of Camsun's labeling?

The FDA Black Box Warnings, which draw attention to serious risks, highlight two major concerns. These are the increased risk of serious cardiovascular thrombotic events (heart attack and stroke) and serious gastrointestinal adverse events (ulcers, bleeding, and perforation).

Q: What official information is provided about the signs and procedures for an accidental overdose of Camsun?

Official information indicates that symptoms of an overdose may include fatigue, drowsiness, nausea, vomiting, and stomach pain. Serious cases may involve stomach bleeding.

Q: Does Camsun have an effect on blood sugar or cholesterol levels?

Patient information from regulatory sources advises that individuals with pre-existing conditions like diabetes or high cholesterol should discuss their treatment with a doctor. These conditions are listed as risk factors for cardiovascular events potentially associated with the medication.

Q: Does Camsun interact with common dental anesthetics or pain management protocols?

Official medical guidance warns that continued use of this type of NSAID near the time of surgery or procedures may result in an increased risk of bleeding. Additionally, regulatory warnings caution that multiple NSAID use (often included in postoperative pain protocols) must be avoided.

How should Camsun be stored and disposed of?

Camsun (Piroxicam) must be stored and disposed of according to official regulatory labeling to ensure its stability and prevent misuse.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F), away from excess heat.
Protection Keep from freezing and protect the container from light and moisture.
Packaging Store in the original container and keep the lid tightly closed to maintain product quality.

Child Safety and Disposal

  • Child Safety: It is mandatory to store Camsun out of the sight and reach of children and pets, in a secure location.
  • Disposal: Unused or expired medication should not be flushed or discarded in household trash (unless following specific FDA home disposal guidance for non-flush list drugs). The official procedure is to dispose of the product according to local regulations, preferably through a community drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Camsun found in:

A-Z Index: